Current Evidence on SGLT-2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data.

IF 2.9 4区医学

Journal of Clinical Pharmacology Pub Date : 2025-04-10 DOI:10.1002/jcph.70026

Fariba Pourkarim, Taher Entezari-Maleki, Haleh Rezaee

引用次数: 0

Abstract

Individuals with prediabetes have a higher risk of cardiovascular events and diabetes mellitus. Therefore, the prevention or delay of prediabetes progression to diabetes via lifestyle modification and medications is an important measure to reduce morbidity and mortality in this population. Based on the American Diabetes Association (ADA) guidelines, metformin is the only recommended drug for prediabetes. A growing body of evidence has shown the beneficial effects of sodium-glucose transporter 2 (SGLT-2) inhibitors in prediabetes. These drugs offer cardiovascular mortality benefits over metformin. This review aimed to summarize current evidence about the clinical effects of SGLT-2 inhibitors in prediabetes.

查看原文本刊更多论文

SGLT-2抑制剂治疗前驱糖尿病的最新证据：临床前和临床数据综述

糖尿病前期患者患心血管疾病和糖尿病的风险更高。因此，通过改变生活方式和药物治疗来预防或延缓糖尿病前期发展为糖尿病是降低这一人群发病率和死亡率的重要措施。根据美国糖尿病协会（ADA）的指南，二甲双胍是唯一推荐用于糖尿病前期的药物。越来越多的证据表明，钠-葡萄糖转运蛋白2 （SGLT-2）抑制剂对前驱糖尿病有有益作用。与二甲双胍相比，这些药物降低了心血管疾病的死亡率。本综述旨在总结目前关于SGLT-2抑制剂在前驱糖尿病中的临床作用的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

自引率

3.40%

发文量

期刊介绍： The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology. This includes original research in pharmacokinetics, pharmacogenetics/pharmacogenomics, pharmacometrics, physiologic based pharmacokinetic modeling, drug interactions, therapeutic drug monitoring, regulatory sciences (including unique methods of data analysis), special population studies, drug development, pharmacovigilance, womens’ health, pediatric pharmacology, and pharmacodynamics. Additionally, JCP publishes review articles, commentaries and educational manuscripts. The Journal also serves as an instrument to disseminate Public Policy statements from the American College of Clinical Pharmacology.